Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer
Grant
US12594321B2
Kind: B2
Apr 07, 2026
Assignee
Novartis AG
Inventors
Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Walter Granda, Ming Lei, Jimin Zhang
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
CPC Classifications
A61K 40/11
A61K 40/31
A61K 40/4221
A61K 2039/505
A61K 2239/48
A61K 2039/804
A61K 35/17
A61P 35/00
A61P 35/02
C07K 16/2803
C07K 16/2887
C07K 2317/622
C07K 2317/56
C07K 2319/03
C07K 2319/33
C07K 14/7051
C12N 5/0636
C12N 5/0646
C12N 15/85
C12N 15/63
C12N 15/86
C12N 2510/00
C12N 2740/10043
C12N 2740/15043
Filing Date
2023-12-05
Application No.
18529915
Claims
18